Ad Header



The Pulse of the Pharmaceutical Industry

Aldeyra’s eye drug found effective in mid-stage study

Written by: | | Dated: Monday, February 29th, 2016

Aldeyra Therapeutics Inc said its experimental eye drug proved to be more effective than a placebo in treating itching associated with allergic conjunctivitis in a mid-stage study.

Allergic conjunctivitis is a common disease characterized by an inflammation of the membrane that covers the eye, which results in excessive tear production, ocular itching, swelling, and redness.

Aldeyra’s experimental drug, NS2, being evaluated in the 100-patient study, was tested in those patients who had at least two-year history of allergic conjunctivitis triggered by grass, tree or ragweed pollen.

Data from the study showed that both single and multiple doses of the drug were statistically significant over a placebo during the trial.

The drug, NS2, was safe during the trial. However, two patients dropped out of the study, the company said on Monday.

NS2 works by trapping small molecules called aldehydes, that are considered to be one of the reasons for inflammatory conditions including allergic conjunctivitis.

Lexington, Massachusetts-based Aldeyra said it is also testing NS2 for another type of eye infection and Sjögren-Larsson Syndrome, a rare genetic condition characterized by dry, scaly skin, as well as eye and neurological problems.



(Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D’Souza and Shounak Dasgupta)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation